The CJC-1295 with DAC and Ipamorelin blend is a dual-peptide research compound combining two of the most studied growth hormone secretagogues in a single lyophilized preparation. CJC-1295 with Drug Affinity Complex (DAC) is a long-acting GHRH analog that binds to albumin in the bloodstream, extending its half-life and enabling sustained stimulation of the GHRH receptor. Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR) known for its specificity in stimulating GH release with minimal effect on cortisol or prolactin in preclinical models.

Research examining the combination of GHRH analogs and GHRP compounds has consistently shown that co-administration produces additive or synergistic increases in growth hormone secretion compared to either compound alone. The CJC-1295 (DAC) component provides sustained baseline receptor stimulation, while Ipamorelin contributes pulsatile GHSR activation — together creating a research model of amplified GH axis activity. Studies have explored downstream effects on IGF-1 levels, nitrogen retention, and body composition in animal research models.

This blend is commonly referenced in growth hormone secretagogue research, pituitary axis studies, and peptide pharmacology investigations. The 5mg/5mg ratio offers a balanced starting point for researchers examining combined GHRH/GHRP activity in preclinical settings.

Disclaimer: This product is intended for in vitro research and laboratory use only. It is not intended for human or veterinary use, consumption, or injection. Not approved by the FDA. Not intended to diagnose, treat, cure, or prevent any disease or medical condition. For use by qualified researchers only.